Avidity Biosciences — Technical Presentation (December 2021)
66 slides from Avidity Biosciences's technical presentation, Dec 9, 2021
Slide 1: Virtual Investor & Analyst Event Series – Volume 3: Delivering on AOCs: FSHD
Virtual Investor & Analyst Event Series – Volume 3 Delivering on AOCs: FSHD Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of
Slide 3: Our Vision
Our Vision To profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics Luke Living with DM1
Slide 4: Delivering on Our Vision
Delivering on Our Vision Progressing robust pipeline in muscle Phase 1/2 MARINATM trial of AOC 1001 ongoing Anticipated clinical trial initiations for both AOC 1044 for DMD and AOC 1020 for FSHD by the end of 2022 Leveraging expertise in clinical and commercial execution Assembling an experienced te
Slide 5: Advancing our Muscle Disease Franchise of AOCs
PROGRAM / INDICATION TARGET DISCOVERY / LEAD OPTIMIZATION IND ENABLING PHASE 1/2 MUSCLE DISORDERS AOC 1001: Myotonic Dystrophy Type 1 (DM1) DMPK AOC 1020: Facioscapulohumeral Muscular Dystrophy (FSHD) DUX4 AOC 1044: Duchenne Muscular Dystrophy (DMD) Exon 44 Dystrophin Next AOC DMD Programs Exon 51 D
Slide 6: Goals for the Day
Goals for the Day Demonstrate how our AOC platform expertise is leveraged across the pipeline Review the preclinical package supporting AOC 1020 Offer a broader perspective on the current treatment landscape for FSHD Answer your questions mAb OLIGO
Slide 7: What’s New: Highlights from Today
What’s New: AOC 1001 Phase 1/2 MARINA trial ongoing: First participants dosed; marked the first time a person was dosed with an AOC Anticipate preliminary assessment of the MARINA trial in Q4 of 2022 Pipeline Progress Announcing AOC 1020 – our candidate for FSHD entering IND enabling studies Anticip
Slide 8: Guest Speaker and Management Presenters
BIOSCIENCES ‘4 AVIDITY GUEST SPEAKER Sarah Boyce, B.S. Art Levin, Ph. D President & CEO CChief Scientific Officer xy M. Statland, M.D. Professor of Neurology att ity ‘of Kansas Medical C W. Michael Flanagan, Ph. D Mike MacLean Chief Technical Officer Chief Financial Ofticer VIDIT 4 AVIDITY
Slide 9: Agenda
Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology University of Kansas Medical Center Sarah Boyce, President and CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology M
Slide 10: Building on our AOC Expertise
Building on our AOC Expertise Art Levin, Ph.D., Chief Scientific Officer
Slide 11: FSHD AOC 1020: Monoclonal antibody linked to an siRNA to DUX4
FSHD AOC 1020 Monoclonal antibody linked to an siRNA to DUX4 mAb siRNA
Slide 12: AOC Components: Data-Driven Component Characteristics
AOC COMPONENTS DATA-DRIVEN COMPONENT CHARACTERISTICS OUR ENGINEERING IMPACT Monoclonal antibody Approved mAbs offer: Well-established safety profiles High specificity and affinity Long half-lives Designed through engineering to be effector function null Epitope selection designed for optimal activit
Slide 13: Durable ~75% Reduction of DMPK mRNA in Monkey Skeletal Muscles
Durable ~75% Reduction of DMPK mRNA Observed in Monkey Skeletal Muscles After a Single Dose of 2mg/kg of siDMPK.19
Slide 14: AOC 1001 siRNA Reduced DMPK mRNA in Wide Range of Skeletal Muscle
The AOC 1001 siRNA Reduced DMPK mRNA in a Wide Range of Skeletal Muscle at Nanomolar Concentrations DMPK Expression in Skeletal Muscle and GI After a Single i.v. Dose in Monkey
Slide 15: AOC 1001 Reduced Muscle DMPK mRNA in Non-human Primates
AOC 1001 Reduced Muscle DMPK mRNA in Concentration Responsive Manner in Non-human Primates Necropsy was at 7 weeks, following 3 doses at 0, 3, and 6 weeks NHP Study 6 Gastrocnemius biopsies collected 21 or 28 days after single doses ranging from 0.6 to 15 mg/kg siRNA EC50 <0.1 nM Day 21 or 28 Post D
Slide 16: Engineering AOCs: Following the Data to Deliver RNA
Engineering AOCs: Following the Data to Deliver RNA AOCs are designed to deliver RNA therapeutics with specificity, potency and precision AOCs are the result of years of in-house engineering AOCs are designed to exploit the well characterized safety and efficacy profiles of approved mAb and siRNA dr
Slide 17: Agenda
Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology University of Kansas Medical Center Sarah Boyce, President and CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology M
Slide 18: Facioscapulohumeral Muscular Dystrophy (FSHD) Program
Facioscapulohumeral Muscular Dystrophy (FSHD) Program W. Michael Flanagan, Ph.D., Chief Technical Officer
Slide 19: Amy, Living with FSHD
Amy, Living with FSHD “Living with FSHD feels like an imprisonment in your own body.”
Slide 20: Delivering on AOCs: FSHD
Delivering on AOCs: FSHD AOCs: Direct targeting of DUX4, the underlying cause of FSHD AOC 1020: Designed to be a potent DUX4 inhibitor moving into IND-enabling studies mAb OLIGO
Slide 21: FSHD is Often Diagnosed in Young Adults with Few Treatment Options
0 APPROVED THERAPIES FSHD is Often Diagnosed in Young Adults with Few Treatment Options There are no approved therapeutics for Facioscapulohumeral Muscular Dystrophy AFFECTS ~16,000 - 38,000 PEOPLE IN THE US One of the most common forms of muscular dystrophy Autosomal dominant disease caused by abno
Slide 22: FSHD is Caused by Aberrant Expression of DUX4
FSHD is Caused by Aberrant Expression of DUX4 DUX4 activates genes that are toxic to muscle cells MECHANISM OF DISEASE THERAPEUTIC APPROACH Apoptotic, immune signaling, altered myogenesis inhibited X X Genetic Signature Shutdown by AOC 1020 X X AOC 1020 DUX4 X Genetic Signature Activated by DUX4 Apo
Slide 23: Small Reductions in DUX4 Expression may have Large Clinical Benefit
Small Reductions in DUX4 Expression may have Large Clinical Benefit Avidity's AOC Targets DUX4 mRNA and is Designed to Eliminate the Cause of FSHD THERAPEUTIC HYPOTHESIS Asymptomatic FSHD MODERATE DUX4 HIGH DUX4 LOW DUX4 Slow/stop disease progression Jones, T.I., et al., Facioscapulohumeral muscular
Slide 24: Delivering on AOCs: FSHD
Delivering on AOCs: FSHD AOCs: Direct targeting of DUX4, the underlying cause of FSHD AOC 1020: Designed to be a potent DUX4 inhibitor moving into IND-enabling studies mAb OLIGO
Slide 25: AOC 1020: Designed to be a Potent and Specific Inhibitor of DUX4
Antibody directed to human Transferrin receptor 1 Non-cleavable linker designed to facilitate siRNA delivery to muscle Stabilized siRNA targeting DUX4 mRNA AOC 1020: FSHD Development Candidate is Designed to be a Potent and Specific Inhibitor of DUX4 Expression AOC 1020 Meets our Target Candidate Pr
Slide 26: AOC 1020 siRNA Inhibited DUX4 Gene Signature in Patient-Derived Myoblasts
AOC 1020 siRNA Showed Potent Inhibition of DUX4-mediated Gene Signature in FSHD-patient Derived Myoblasts IC50 = 0.127 nM FSHD Donor MB05 DUX4 gene signature (% mock) THERAPEUTIC APPROACH Apoptotic, immune signaling, altered myogenesis inhibited X X Genetic Signature Shutdown by AOC 1020 X X AOC 102
Slide 27: AOC 1020: Designed to be a Potent and Specific Inhibitor of DUX4
Antibody directed to human Transferrin receptor 1 Non-cleavable linker designed to facilitate siRNA delivery to muscle Stabilized siRNA targeting DUX4 mRNA AOC 1020: FSHD Development Candidate is Designed to be a Potent and Specific Inhibitor of DUX4 Expression AOC 1020 Meets our Target Candidate Pr
Slide 28: Transgenic DUX4 Mouse Model Recapitulates Key Features of FSHD
Transgenic DUX4 Mouse Model* Recapitulates Key Features of FSHD in Humans FSHD-like Mouse Model FSHD Aberrant DUX4 Muscle expression Muscle weakness Moderate DUX4 expression Disease Progression Fast Slow DUX4 Gene signature (apoptosis, immune signaling, aberrant myogenesis) *ACTA1-MCM x FLexDUX4 mic
Slide 29: AOC 1020 siRNA Inhibited DUX4 Gene Signature in Transgenic Mouse Model
AOC 1020 siRNA Showed Potent Inhibition of DUX4 Gene Signature in Transgenic Mouse Model Dose-dependent inhibition of DUX4-driven genes in skeletal muscles Next Steps: Functional studies are currently underway to support Phase 1 dose selection Gastrocnemius Gastrocnemius DUX4 gene signature (% mock)
Slide 30: AOC 1020 Nonclinical Activities Progressing to Support 2022 IND Filing
AOC 1020 Nonclinical Activities Progressing Well to Support 2022 IND Filing No dose limiting toxicity observed in monkeys at the highest dose tested based on in-life safety assessments Supports study design for GLP toxicology studies AOC 1020 PK results consistent with anticipated exposure based on
Slide 31: AOC 1020 Plasma PK Results in Monkey
AOC 1020 Plasma PK Results in Monkey Demonstrated Stability of the Antibody-Oligonucleotide Conjugate AOC 1020 produced dose-dependent increase in siRNA plasma exposure following single doses AOC 1020 was observed to be stable in plasma with no evidence for degradation of the intact AOC AOC 1020 at
Slide 32: AOC 1020 PK Results in NHP Muscle Tissue
AOC 1020 PK Results in NHP Muscle Tissue Potentially Support an Infrequent Dosing Regimen AOC 1020 produced dose-dependent increase in siRNA tissue exposure following single doses in a broad panel of muscle tissue Based on our data, we anticipate this will allow for a similar dose schedule as AOC 10
Slide 33: Approaching the Clinic
APPROACHING THE CLINIC Planned clinical trial initiation by the end of 2022 DELIVERING ON FSHD Observed reduced expression of key DUX4 gene signature in FSHD patient myotubes and in FSHD mouse disease model Well tolerated in cynomolgus monkey preclinical studies at all doses and dose frequencies tes
Slide 34: Agenda
Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology University of Kansas Medical Center Sarah Boyce, President and CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology M
Slide 35: Jeffrey M. Statland, M.D.
Jeffrey M. Statland, M.D. Professor of Neurology, University of Kansas Medical Center in Kansas City, Kansas
Slide 36: Jeffrey M. Statland, M.D. Biography
Jeffrey M. Statland, M.D. is a Professor of Neurology at the University of Kansas Medical Center in Kansas City, Kansas. His research background has centered primarily on describing the natural history of and response to therapy for neuromuscular diseases. Dr. Statland completed a neuromuscular fell
Slide 37: FSHD: Disease Overview and Endpoints
FSHD: Disease Overview and Endpoints Avidity, December 2021 Jeffrey Statland, MD Professor of Neurology, University of Kansas Medical Center J Biol Chem. 2018 Jul 27;293(30):11837-11849.
Slide 38: Disclosures
Disclosures Grant funding from: NINDS, FSHD Society, Friends of FSH Research, FSHD Canada, MDA Consultant or Ad Board: Acceleron, Dyne, Avidity, Fulcrum, Roche, Sarepta, MT Pharma, ML Bio, and Expansion
Slide 39: Overview
Overview FSHD disease mechanism Biomarkers ( eg , transcriptome, MRI) ReSolve /MOVE Natural history update
Slide 40: FSHD: One of the Most Common Muscular Dystrophies
FSHD One of the most common muscular dystrophies Worldwide Prevalence 2-7/100,000 ~ 21,000 in US No clear racial or ethnic predispositions Can lead to significant morbidity ~20% becoming disabled or requiring full-time wheelchair use Diagnosis is based on characteristic clinical presentation and gen
Slide 41: FSHD: Inheritance
FSHD: Inheritance Two genetically distinct forms Clinically similar – converge on common downstream pathway Type 1: ~95% due to deletion of repetitive element (D4Z4 region) on chromosome 4q35 (normal >10, FSHD 1-10) Autosomal dominant inheritance Up to 30% spontaneous Type 2: ~5% deletion-independen
Slide 42: FSHD in a Nutshell
FSHD in a Nutshell A gene, DUX4, that is normally turned off gets turned on DUX4 is toxic to muscle cells (Image courtesy of Stephen Tapscott, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle WA)
Slide 43: FSHD Unified Model
FSHD Unified Model: a normally silenced gene gets ‘turned on’ DNMT3B - Necessary for FSHD Decreased methylation D4Z4 region Permissive A polymorphism
Slide 44: What is DUX4?
What is DUX4? DUX4 (Double Homeobox 4) is a transcription factor normally expressed in the human germline but not in somatic cells Role in cleavage-specific transcriptional programs (morula=>blastula) DUX4 activates the expression of many hundreds of genes including cancer testis antigens genes invo
Slide 45: Therapeutic Approaches Targeting the FSHD Pathway
A AON/CRSPR/CAS9: Splice site SMCHD1/DNMT3B Mutations; or polyadenylation seq RNAi: Interference RNA Downstream Effects Immune Suppression Antioxidants Methylate DNA? Block apoptosis FSHD1 / FSHD2 AON: targeting poly a tail Small molecules DUX4 mRNA
Slide 46: Clinical Spectrum of FSHD: Pattern of Motor Involvement
While characteristic initial pattern of motor involvement, recent MRI studies suggest earlier involvement of paraspinal, pelvic girdle, and thigh muscles than previously appreciated – ambulatory assessments may be important early Clinical Spectrum of FSHD Lek A, et al. Trends Mol Med. 2015;21(5):295
Slide 47: Clinical Spectrum of FSHD
Can affect people from birth through old age (median ~20 years) Considerable variability between individuals and even within single families from generation to generation (or within an individual = side to side asymmetry) No clear clinical difference FSHD1 v FSHD2 Restrictive respiratory disease in
Slide 48: Patient Surveys
Patient Surveys Outcomes which measure weakness in UEXT, core, LEXT identified as important to patients FSHD Society Voice of the Patient: https://www.fshdsociety.org/fsh-events/vopf/ Patient Experience of FSHD Hamel J, et al. Neurology. 2019 Aug 13. [Epub ahead of print] PubMed PMID: 31409737
Slide 49: Overview
Overview FSHD disease mechanism Biomarkers ( eg , transcriptome, MRI) ReSolve /MOVE Natural history update
Slide 50: DUX4-regulated Genes More Reliably Detected
DUX4-regulated genes more reliably detected The obvious choice DUX4, but only detected sparsely (~1:1000 nuclei) DUX4-regulated genes more reliably detected (microarray, RNA seq, qPCR) Similar DUX4-regulated targets used preclinically (drug screening, inducible animal models) Human muscle biopsies B
Slide 51: DUX4 Biomarkers Correlate with Disease
DUX4 Biomarkers correlate with disease Broad but consistent range, stability in population mean over 1 year within subject variability (ICC ~0.64) Better reliability at shorter timeframe in Fulcrum phase 0 study Correlation to muscle pathology Strong face validity: if DUX4 causes disease by toxic ga
Slide 52: MRI as a Biomarker Supplementing Gene Expression Changes
MRI: as a biomarker supplementing gene expression changes STIR signal on MRI in affected muscles can increase DUX4-related biomarker sensitivity to 90-95% MRI can also be used to monitor disease progression Combined strength measures change at about 2-4% per year; so do average muscle MRI qFat measu
Slide 53: Overview
Overview FSHD disease mechanism Biomarkers ( eg , transcriptome, MRI) ReSolve /MOVE Natural history update
Slide 54: Prior Natural History Study (1997)
Prior Natural History Study (1997) Natural history study (n=81 subjects, up to 3 years) Two methods used widely in FSHD Manual Muscle Testing (MMT) can include many muscles, weak muscles Quantitative Myometry (QMT) continuous measure, can be normalized MMT used in FDA approval of deflazacort for DMD
Slide 55: FSHD Clinical Trial Research Network (CTRN) Sites
FSHD Clinical Trial Research Network (CTRN) Sites Coming Soon: Institute of Myology University of Munich University College London University of Ottawa McGill University Funding from all stakeholders: patients, advocacy, NIH, and industry
Slide 56: Current Natural History Studies for FSHD
Current Natural History Studies for FSHD ReSolve (NCT03458832): 300 individuals x 24 months (8 sites US and 6 UK/EU) validate outcomes (e.g. FSHD Composite, EIM) Evaluate new outcomes (reachable workspace, IOPI) Refine I/E ReSolve France (NCT04038138) MOVE/MOVE+ (NCT04635891): 450 individuals x 36 m
Slide 57: ReSolve: FSHD-Composite (FSHD-COM)
ReSolve: FSHD-Composite (FSHD-COM) Functional composite matching patient-reported domains of functional impairment 18 evaluator administered items, scale 0-72 points Excellent test-retest reliability (ICC>0.9) MDC90: ~10% change Moderate to strong cross-sectional associations to disease duration, st
Slide 58: ReSolve Update
ReSolve Update 240 enrolled, ~157 at 12 months, ~130 at 18 months, and 100 at 24 months We see progression over multiple outcome measures FSHD-COM and most components Changes about 10% at 2 years RWS can select groups most likely to progress / used successfully in a phase 2 clinical trial EIM may se
Slide 59: MOVE+ Schedule of Activities
MOVE+ Schedule of Activities Follow up to ReSolve Allows us to follow people for another 3 years MOVE: currently n=140 enrolled; MOVE+ to start Jan 2022
Slide 60: Conclusion
Conclusion FSHD - the molecular basis is defined DUX4 is a clear molecular target for therapy Recently completed clinical trials to learn from Multiple candidate functional/strength outcomes for registration trial Ongoing natural history studies to help overcome barriers to trial design What will a
Slide 61: Agenda
Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology University of Kansas Medical Center Sarah Boyce, President and CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology M
Slide 62: Q&A
Q&A Participants: Avidity Management Jeffrey M. Statland, M.D. Moderator: Mike MacLean, CFO
Slide 63: Agenda
Agenda Sarah Boyce, President & CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology University of Kansas Medical Center Sarah Boyce, President and CEO Art Levin, Ph.D., CSO Mike Flanagan, Ph.D., CTO Jeffrey M. Statland, M.D., Professor of Neurology M
Slide 64: Closing Remarks
Closing Remarks Sarah Boyce, President & CEO
Slide 65: Goals for the Day
Goals for the Day Demonstrate how our AOC platform expertise is leveraged across the pipeline Review the preclinical package supporting AOC 1020 Offer a broader perspective on the current treatment landscape for FSHD Answer your questions mAb OLIGO
Slide 66: Delivering on the RNA Revolution
Delivering on the RNA Revolution Phase 1/2 MARINA trial of AOC 1001 ongoing AOC 1020 for FSHD & AOC 1044 for DMD anticipated to enter the clinic by the end of 2022 Pursuing preclinical proof of concept in additional skeletal muscle and other tissues DELIVERING NEXT Luke Living with DM1
Avidity Biosciences — Technical Presentation (December 2021) on 6ix